Tobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: a case-control study

dc.authorid0000-0003-0731-9244
dc.authorid0000-0002-6044-7328
dc.authorid0000-0002-5880-6352
dc.contributor.authorWang, Xingyu
dc.contributor.authorLiu, Xin
dc.contributor.authorO'Donnell, Martin J.
dc.contributor.authorMcQueen, Matthew
dc.contributor.authorSniderman, Allan
dc.contributor.authorPare, Guillaume
dc.contributor.authorHankey, Graeme J.
dc.date.accessioned2025-05-10T19:49:10Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground Smoking is a major risk factor for the global burden of stroke. We have previously reported a global population attributable risk (PAR) of stroke of 12.4% associated with current smoking. In this study we aimed to explore the association of current tobacco use with different types of tobacco exposure and environmental tobacco smoke (ETS) exposure on the risk of stroke and stroke subtypes, and by regions and country income levels. Methods The INTERSTROKE study is a case-control study of acute first stroke and was undertaken with 13,462 stroke cases and 13,488 controls recruited between January 11, 2007 and August 8, 2015 in 32 countries worldwide. Association of risk of tobacco use and ETS exposure were analysed with overall stroke, ischemic and intracerebral hemorrhage (ICH), and with TOAST etiological stroke subtypes (large vessel, small vessel, cardioembolism, and undetermined). Findings Current smoking was associated with an increased risk of all stroke (odds ratio [OR] 1.64, 95% CI 1.46-1.84), and had a stronger association with ischemic stroke (OR 1.85, 95% CI 1.61-2.11) than ICH (OR 1.19 95% CI 1.00-1.41). The OR and PAR of stroke among current smokers varied significantly between regions and income levels with high income countries (HIC) having the highest odds (OR 3.02 95% CI 2.24-4.10) and PAR (18.6%, 15.1-22.8%). Among etiological subtypes of ischemic stroke, the strongest association of current smoking was seen for large vessel stroke (OR 2.16, 95% CI 1.63-2.87) and undetermined cause (OR 1.97, 95% CI 1.55-2.50). Both filtered (OR 1.73, 95% CI 1.50-1.99) and non -filtered (OR 2.59, 95% CI 1.79-3.77) cigarettes were associated with stroke risk. ETS exposure increased the risk of stroke in a dose -dependent manner, exposure for more than 10 h per week increased risk for all stroke (OR 1.95, 95% CI 1.69-2.27), ischemic stroke (OR 1.89, 95% CI 1.59-2.24) and ICH (OR 2.00, 95% CI 1.60-2.50). Interpretation There are significant variations in the magnitude of risk and PAR of stroke according to the types of tobacco used, active and ETS exposure, and countries with different income levels. Specific strategies to discourage tobacco use by any form and to build a smoke free environment should be implemented to ease the global burden of stroke. Copyright (c) 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.description.sponsorshipStroke Network; Swedish Research Council; Swedish Heart and Lung Foundation; Health & Medical Care Committee of the Regional Executive Board; Astra Zeneca; Pfizer (Canada); MERCK, Sharp and Dohme; Swedish Heart and Lung Foundation, UK Chest; UK Heart and Stroke
dc.description.sponsorshipThe Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, Swedish Research Council, Swedish Heart and Lung Foundation, The Health & Medical Care Committee of the Regional Executive Board, Region Vastra Gotaland, and through unrestricted grants from several pharmaceutical companies with major contributions from Astra Zeneca, Boehringer Ingelheim (Canada), Pfizer (Canada), MERCK, Sharp and Dohme, Swedish Heart and Lung Foundation, UK Chest, and UK Heart and Stroke.r Stroke Network, Swedish Research Council, Swedish Heart and Lung Foundation, The Health & Medical Care Committee of the Regional Executive Board, Region Vastra Gotaland, and through unrestricted grants from several pharmaceutical companies with major contributions from Astra Zeneca, Boehringer Ingelheim (Canada) , Pfizer (Canada) , MERCK, Sharp and Dohme, Swedish Heart and Lung Foundation, UK Chest, and UK Heart and Stroke.
dc.identifier.doi10.1016/j.eclinm.2024.102515
dc.identifier.issn2589-5370
dc.identifier.pmid38516107
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.eclinm.2024.102515
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11949
dc.identifier.volume70
dc.identifier.wosWOS:001210385600001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEclinicalmedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectStroke subtypes
dc.subjectTobacco
dc.subjectEnvironmental smoking
dc.subjectRisk factor
dc.subjectInternational
dc.titleTobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: a case-control study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
11949.pdf
Boyut:
678.59 KB
Biçim:
Adobe Portable Document Format